A Phase 2 12-Week Adaptive Open Label Sequential Cohort Trial to Evaluate the Efficacy Safety Tolerability and Pharmacokinetics of PF06730512 Following Multiple Doses in Adult Subjects with Focal Segmental Glomerulosclerosis (FSGS)

Brief description of study

The purpose of this research study is to learn about the effects, overall safety, how well people can tolerate (tolerability) the study drug (PF-06730512), and to see how much drug is in the blood (pharmacokinetics), following intravenous administration every two weeks over 12 weeks. Intravenous administration means that the study drug is infused into one of the veins on the arm. The primary goal of this study is to obtain an early sign that the drug works. PF-06730512 is an investigational drug. An investigational drug is one that is currently not approved for sale in the United States or any other country. Investigational drugs administered in clinical studies are also commonly known as study drugs.

Clinical Study Identifier: s20-00712
ClinicalTrials.gov Identifier: NCT03448692
Principal Investigator: Safa M. Kalache.
Other Investigator: Olga Zhdanova.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.